Access & Resources

Getting
started with
XACDURO

Ordering Info

Contact a distributor

To order XACDURO, please contact one of the distributors below.

If you would like more information about XACDURO or have questions related to research, please contact a

Medical Science Liaison
.

Slide table to view more

NDC CodeDistributorsContact Information

NDC 68547-111-10

XACDURO is a co-packaged product containing:

  • 1 g sulbactam in one single‑dose vial
  • 1 g durlobactam in two single-dose vials (0.5 g durlobactam in each single‑dose vial)

Each single-dose vial contains sterile powders for reconstitution

ASD Healthcare is now AmerisourceBergen specialty distribution
1-800-746-6273
asd.customerservice@asdhealthcare.com
Cardinal Health Specialty Pharmaceutical Distribution
1-866-677-4844
McKesson Plasma and Biologics
1-877-625-2566
Resources

Downloadable practice tools

XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use brochure

Brochure

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use patient profile 1

Patient Profile 1

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use patient profile 2

Patient Profile 2

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use dosing card

Dosing Card

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use instructions for use

Instructions for Use

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use ordering sheet

Ordering Sheet

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use microbiology brochure

Microbiology Brochure

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use susceptibility testing brochure

Antimicrobial Susceptibility
Testing Brochure

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use NTAP designation hospital brochure

NTAP Designation
Hospital Brochure

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use billing and coding guide

Billing and Coding
Reference Guide

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use critical care brochure

Critical Care Brochure

Download now
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use stewardship brochure

Stewardship Brochure

Download now

Want to know more?

Request to speak with a XACDURO sales representative or receive information.

Treat with Precision.

Choose pathogen-targeted coverage for HABP/VABP caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex with XACDURO.1

Order XACDURO

Reference:

1. Kaye KS, et al. Lancet Infect Dis. 2023;11:s1473‑3099(23)00184‑6. doi:10.1016/s1473‑3099(23)00184‑6

Indication & Usage

Indication & Usage

Indication

XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

Limitations of Use

XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XACDURO and other antibacterial drugs, XACDURO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Before administering, please see the Full Prescribing Information for XACDURO.

Important Safety Information

Indication & Usage

Indication

XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

Limitations of Use

XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XACDURO and other antibacterial drugs, XACDURO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Before administering, please see the Full Prescribing Information for XACDURO.

Important Safety Information

Contraindications: XACDURO is contraindicated in patients with a history of known severe hypersensitivity to the components of XACDURO or other beta-lactam antibacterial drugs.

Warnings and Precautions:

  • Hypersensitivity was observed in patients treated with XACDURO in clinical trials. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before initiating therapy with XACDURO, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta lactams, and other allergens. If an allergic reaction occurs, discontinue XACDURO.
  • Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. If CDAD is suspected or confirmed, the risk/benefit of continuing treatment with XACDURO should be assessed.
  • Prescribing XACDURO in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse Reactions: The most common adverse reactions reported in >10% of patients treated with XACDURO were liver test abnormalities (19%), diarrhea (17%), anemia (13%), and hypokalemia (12%).

You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, please contact:

Innoviva Specialty Therapeutics, Inc.™
1-800-651-3861
medinfo@istx.com
U.S. Food and Drug Administration
1-800-FDA-1088
www.fda.gov/medwatch

Before administering, please see the Full Prescribing Information for XACDURO.

Indication & Usage

Indication

XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

Limitations of Use

XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XACDURO and other antibacterial drugs, XACDURO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Before administering, please see the Full Prescribing Information for XACDURO.

Important Safety Information

Contraindications: XACDURO is contraindicated in patients with a history of known severe hypersensitivity to the components of XACDURO or other beta-lactam antibacterial drugs.

Warnings and Precautions:

  • Hypersensitivity was observed in patients treated with XACDURO in clinical trials. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before initiating therapy with XACDURO, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta lactams, and other allergens. If an allergic reaction occurs, discontinue XACDURO.
  • Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. If CDAD is suspected or confirmed, the risk/benefit of continuing treatment with XACDURO should be assessed.
  • Prescribing XACDURO in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse Reactions: The most common adverse reactions reported in >10% of patients treated with XACDURO were liver test abnormalities (19%), diarrhea (17%), anemia (13%), and hypokalemia (12%).

You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, please contact:

Innoviva Specialty Therapeutics, Inc.™
1-800-651-3861
medinfo@istx.com
U.S. Food and Drug Administration
1-800-FDA-1088
www.fda.gov/medwatch

Before administering, please see the Full Prescribing Information for XACDURO.

  • Prescribing Information
  • Important Safety Information
  • Ordering Info
  • Medwatch
  • Contact Us
  • Privacy Policy
  • Terms of Use

XACDURO® is marketed by Innoviva Specialty Therapeutics, Inc.

© 2026 Innoviva Specialty Therapeutics™. All rights reserved. PR‑SUL‑US‑0013 v6.0 | 05/26